Navigation Links
ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Date:12/10/2009

LEUVEN, Belgium, December 11 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD).

Wet AMD affects approximately five million patients worldwide and this patient population is continuing to grow. Wet AMD occurs when abnormal blood vessels behind the retina start to grow under the macula, the central area of the retina responsible for detailed vision. These blood vessels are often fragile and can leak blood and fluid below the macula, causing damage to the photoreceptors and vision loss. AMD, a disease associated with aging, gradually destroys a patient's vision. It is the most common cause of vision loss in patients aged 50 or older, and represents a market of over $1 billion annually.

Abnormalities in the vitreomacular interface (the interface of the vitreous and macula) have been implicated in wet AMD, and recent publications have demonstrated that approximately one-third of AMD patients have focal vitreomacular adhesion (VMA). VMA is a condition in which the vitreous gel, in the center of the eye, has an abnormally strong adhesion to the retina at the back of the eye, and research has found that this adhesion occurs in the same location as the wet AMD pathology.[1]

ThromboGenics is developing microplasmin as a non-surgical treatment for vitreomacular adhesion. Microplasmin has the potential to separate the vitreous from the retina and, as wet AMD is thought to result from the abnormal connection of the vitreous to the retina, it is therefore anticipated that microplasmin could potentially prevent the progression of this highly prevalent disease.

The MIVI 5 (Microplasmin for IntraVitreous Injection) trial is a P
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
3. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
4. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
7. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
8. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
11. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:7/11/2014)... Emily Johnson, owner of the Portland Fit Body ... boot camp has held two charity workout events and is ... 26th, from 7:15 - 8:30 at Col Summers City Park, SE ... camp session raised $510 for Medical Teams International. Their second workout ... a Dream. On July 26th, Johnson and Portland Fit Body ...
(Date:7/11/2014)... 2014 As reported by Forbes in ... Are Genetics To Blame (6/30), Indino Downey has reportedly ... paraphernalia to smoke it with. His father, well-known actor ... son inherited from him may have something to do ... news during the 1980s and 1990s for substance abuse ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 ... today announces that he uses mini and full mouth ... offer the defining feature that distinguishes dental implants from ... in addition to the crowns. This alone prevents the ... also offer advantages related to comfort, appearance and ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Polio is history ... places like Afghanistan, Nigeria and Pakistan. Giving vaccinated children ... their immunity and help eradicate the highly infectious disease, ... is highly effective, immunity wanes as early as a ... be infected and contribute to the spread of the ...
(Date:7/11/2014)... For breast cancer patients, the era of personalized medicine ... advances by USC Stem Cell researcher Min Yu and ... , In a July 11 study in Science ... breast cancer cells circulating through the blood streams of ... the "seeds" of metastasis, which travel to and establish ...
Breaking Medicine News(10 mins):Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 3Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:Researchers Assess New Way to Boost Polio Immunity 2
... by the Canadian Association for Adolescent Health has found that ... are ignorant about important sex information.// ,The survey ... in casual sex and a half-million sexually active teens aged ... of teens claimed to have some knowledge about sex, but ...
... The infant formula Gentlease is being recalled from the market ... of metal particles in some cans. // So this brand ... makers of Gentlease powdered infant formula, Mead Johnson Nutritionals of ... batch number BMJ19 printed on the bottom of the cans. ...
... that swimming helps immensely the children to stay hale ... ,Researches conducted over six years at the Jigalong, ... examined the impact on children's health where swimming pools ... Institute for Child Health Research study found that at ...
... can do more than affecting just your gums. It ... premature delivery. // The following is the conclusion arrived ... York. ,Participants at the conference highlighted the ... association with gum disease. They further reflected the need ...
... level of which is strongly suggestive of prostate cancer in ... early signs of prostate cancer, // if any. A new ... needed for establishment of prostate cancer diagnosis in young men ... researchers from Duke University Medical Center analyzed more than 12,000 ...
... who is the principle investigator said that the new technique ... to discover molecules that can enhance or block different kinds ... succeeded in growing mature taste receptor cells outside the body. ... for a prolonged period of time. This is a break ...
Cached Medicine News:Health News:Unhealthy Gums Increase Risk Of Premature Delivery 2Health News:Functional Taste Cells Cultured In Vitro 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: